Table 2.
Kaplan–Meier estimates: median time in months to therapy discontinuation (95% confidence intervals) and probabilities (95% confidence intervals) of therapy discontinuation at 6, 12, and 24 months of follow-up for entire cohort and stratified by prior use of BRAF/MEK inhibitors, presence of brain metastases at baseline, and sex.
| Therapy discontinuation | Pembrolizumab | Nivolumab | Nivolumab/ipilimumab |
|---|---|---|---|
| All patients (N = 876) | |||
| Median time to discontinuation (months) | 12.1 (11.2–14.0) | 9.3 (6.8–11.9) | 7.9 (5.5–10.6) |
| 6 months | 23.6% (19.2–28.7) | 37.3% (30.5–45.2) | 44.9% (38.2–52.1) |
| 12 months | 49.9% (43.6–56.5) | 58.8% (50.5–67.3) | 59.2% (51.7–66.8) |
| 24 months | 73.7% (64.9–81.8) | 73.3% (63.8–82.0) | 72.0% (63.1–80.3) |
| Patients with prior use of BRAF/MEK inhibitors (N = 94) | |||
| Median time to discontinuation (months) | 11.4 (6.8–24.1) | 11.9 (4.7–25.7) | 5.4 (4.7–NA) |
| 6 months | 27.3% (15.2–46.0) | 34.7% (17.1–62.0) | 50.1% (28.7–76.2) |
| 12 months | 53.3% (35.6–73.3) | 56.4% (31.2–84.3) | 60.1% (35.9–85.0) |
| 24 months | 65.0% (45.4–83.8) | 56.4% (31.2–84.3) | 60.1% (35.9–85.0) |
| Patients without prior use of BRAF/MEK inhibitors (N = 782) | |||
| Median time to discontinuation (months) | 12.1 (10.8–15.2) | 8.7 (6.7–11.5) | 7.9 (5.5–10.6) |
| 6 months | 23.1% (18.6–28.5) | 37.7% (30.5–46.0) | 44.5% (37.6–52.0) |
| 12 months | 49.4% (42.7–56.4) | 58.9% (50.2–67.7) | 59.2% (51.4–67.2) |
| 24 months | 74.8% (65.3–83.4) | 74.7% (64.8–83.7) | 73.1% (63.8–81.7) |
| Patients with brain metastases at baseline (N = 244) | |||
| Median time to discontinuation (months) | 11.2 (7.9–13.1) | 8.7 (4.9–14.5) | 13.4 (5.7–19.6) |
| 6 months | 26.8% (18.3–38.3) | 43.0% (29.2–59.9) | 36.3% (24.5–51.6) |
| 12 months | 54.4% (41.5–68.4) | 61.5% (45–78.2) | 49.0% (34.7–65.4) |
| 24 months | 82.1% (64.2–94.4) | 71.1% (50.1–89.1) | 73.2% (52.3–90.4) |
| Patients without brain metastases at baseline (N = 632) | |||
| Median time to discontinuation (months) | 12.6 (11.2–16.1) | 9.5 (6.8–13.6) | 6.5 (5.4–9.1) |
| 6 months | 22.5% (17.7–28.3) | 35.8% (28.1–44.9) | 47.9% (40.2–56.2) |
| 12 months | 48.5% (41.4–56.2) | 58.0% (48.5–67.8) | 62.6% (54.0–71.2) |
| 24 months | 71.8% (61.5–81.4) | 73.9% (63.2–83.5) | 71.8% (62.3–80.6) |
| Men (N = 577) | |||
| Median time to discontinuation (months) | 13.3 (11.4–16.1) | 8.7 (6.7–15.2) | 8.2 (5.7–13.4) |
| 6 months | 21.2% (16.0–27.7) | 36.6% (28.1–46.7) | 41.7% (33.8–50.6) |
| 12 months | 48.2% (40.1–57.0) | 56.8% (46.4–67.6) | 55.2% (46.1–64.7) |
| 24 months | 73.6% (62.2–83.9) | 70.3% (57.6–82.0) | 68.6% (57.5–79.2) |
| Women (N = 319) | |||
| Median time to discontinuation (months) | 11.2 (8.9–13.6) | 10.1 (5.5–12.4) | 6.0 (4.8–9.1) |
| 6 months | 27.3% (20.3–36.1) | 38.5% (27.7–51.7) | 51.0% (39.6–63.6) |
| 12 months | 52.4% (42.9–62.7) | 61.6% (48.3–75.1) | 67.2% (54.2–79.6) |
| 24 months | 73.2% (60.0–84.9) | 77.7% (63.1–89.5) | 79.0% (63.9–90.9) |
NA not available.